Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib

Bleeding because of impaired platelet function is a major side effect of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib. We quantitatively assessed ristocetin-induced platelet aggregation (RIPA) in 64 patients with chronic lymphocytic leukemia (CLL) under ibrutinib at 287 time points. E...

詳細記述

保存先:
書誌詳細
出版年:Leukemia
主要な著者: Kazianka, L, Drucker, C, Skrabs, C, Thomas, W, Melchardt, T, Struve, S, Bergmann, M, Staber, P B, Porpaczy, E, Einberger, C, Heinz, M, Hauswirth, A, Raderer, M, Pabinger, I, Thalhammer, R, Egle, A, Wendtner, C-M, Follows, G, Hoermann, G, Quehenberger, P, Jilma, B, Jaeger, U
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group 2017
主題:
Original Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5338745/
https://ncbi.nlm.nih.gov/pubmed/27909342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2016.316
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料